EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Intraperitoneal Gemcitabine Chemotherapy Treatment for Patients with Resected Pancreatic Cancer: Rationale and Report of Early Data

Paul H Sugarbaker, O Anthony Stuart, Lana Bijelic

International Journal of Surgical Oncology · 2011

DOI: 10.1155/2011/161862 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Surgical Oncology, 2011. Verfasst von Paul H Sugarbaker und 2 weiteren Autor:innen. Beteiligte Einrichtung: Washington Cancer Institute, 106 Irving Street, NW, Suite 3900, Washington, DC 20010, USA. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Currently, the surgical management of pancreas cancer is recognized around the world as inadequate. Despite a potentially curative R0 resection, long-term survival is rare. There is a strong rationale for the use of chemotherapy in the operating room to reduce local-regional of recurrent/progressive disease. Gemcitabine monotherapy administered by an intraperitoneal route in the operating room with hyperthermia and then for long-term treatment postoperatively has a pharmacologic basis in that the exposure of peritoneal surfaces to intraperitoneal gemcitabine is approximately 200–500 times the exposure that occurs within the plasma. A standardized treatment with intraoperative and long-term chemotherapy that is well tolerated would greatly facilitate further improvements in pancreas cancer treatment and may lead the way to an evolution of more successful treatment strategies of this dread disease. The aim of this paper is to present the early data on a protocol in progress in patients with resected pancreatic cancer.

Autor:innen und Institutionen

  • Washington Cancer Institute, 106 Irving Street, NW, Suite 3900, Washington, DC 20010, USA.

Zitieren

APA

Sugarbaker, P. H., Stuart, O. A., & Bijelic, L. (2011). Intraperitoneal Gemcitabine Chemotherapy Treatment for Patients with Resected Pancreatic Cancer: Rationale and Report of Early Data. International Journal of Surgical Oncology. https://doi.org/10.1155/2011/161862

Vancouver

Sugarbaker PH, Stuart OA, Bijelic L. Intraperitoneal Gemcitabine Chemotherapy Treatment for Patients with Resected Pancreatic Cancer: Rationale and Report of Early Data. International Journal of Surgical Oncology. 2011. doi:10.1155/2011/161862

BibTeX
@article{Sugarbaker2011,
  author = {Sugarbaker, Paul H and Stuart, O Anthony and Bijelic, Lana},
  title = {Intraperitoneal Gemcitabine Chemotherapy Treatment for Patients with Resected Pancreatic Cancer: Rationale and Report of Early Data},
  journal = {International Journal of Surgical Oncology},
  year = {2011},
  doi = {10.1155/2011/161862}
}
Kostenlos starten →